Compare ACNT & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACNT | ELDN |
|---|---|---|
| Founded | 1945 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.0M | 235.1M |
| IPO Year | 1995 | 2014 |
| Metric | ACNT | ELDN |
|---|---|---|
| Price | $13.76 | $3.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 120.0K | ★ 1.4M |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 106.72 | 30.67 |
| EPS | ★ 0.09 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $152.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.62 | $1.35 |
| 52 Week High | $17.92 | $4.60 |
| Indicator | ACNT | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 51.62 | 65.89 |
| Support Level | $13.66 | $2.45 |
| Resistance Level | $16.80 | $3.51 |
| Average True Range (ATR) | 0.41 | 0.20 |
| MACD | 0.21 | 0.01 |
| Stochastic Oscillator | 89.66 | 84.22 |
Ascent Industries Co specializes in development, production, and distribution of specialty chemicals. The company produces specialty ingredients and products for the oil and gas, household, industrial and institutional, personal care, coatings, adhesive, sealants, elastomers, pulp and paper, textile, automotive, agricultural, water, treatment, and construction industries. The products of the company include: Surfactants, Defoamers, Flame Retardants, Emulsifiers, Lubricants, Plasticizers, Straight Esters and Others.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.